Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-start_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-start_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-start_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-start_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-start_date" }, "data": [ { "type": "Grant", "id": "5542", "attributes": { "award_id": "3U54MD007602-33S3", "title": "Center for Translational Research in Health Disparities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 19246, "first_name": "Priscah", "last_name": "Mujuru", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-07-07", "end_date": "2023-05-31", "award_amount": 177500, "principal_investigator": { "id": 19247, "first_name": "Vincent C", "last_name": "Bond", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 755, "ror": "https://ror.org/01pbhra64", "name": "Morehouse School of Medicine", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract: Diversity in the rates of progression and mortality of COVID-19 disease within infected African American (AAs) subgroups are clearly not just a function of the underlying health conditions that increase the rate of mortality for COVID -19 patients, such as hypertension, obesity and diabetes, but may also be affected by host genetic factors. Here we propose a series of studies to advance the understanding of our knowledge in relative to the health inequity in COVID-19 disease. This is a multiple-collaborative study between Genomic, Imaging research labs and Statistical studies. Research teams in Morehouse School of Medicine (MSM) have established intimate relationships that position the institute to focus their research works on underserved minorities. We plan to develop and disseminate technological approaches in identifying host factors that disproportionately affect AAs COVID-19 infected patients. Given that the discovery, and establishment of translational implementation of novel solutions to health disparities in high-risk minority COVID-19 infected is our overall goals. Recently, angiotensin-converting enzyme 2 (ACE2), encoded on the X-chromosome, has been shown to be a functional receptor for COVID-19 to enter host target cells and the concern might arise regarding whether ACE2 variants between and within subgroups would increase the morbidity and mortality of COVID-19 infected patients. Therefore, the long-term goal is to compare how genetic variants of the ACE2 receptor, chemokine (CCL2) and human leukocyte antigen (HLA) genes (influence the immune system’s response to viruses and bacteria), affects COVID-19 disease severity among people but no underlining disease like diabetes, heart or lung disease with those with mild or no disease manifestations. Short-term goal; we will focus on two aims; Aim: 1-Determine genetic variations in ACE2 gene on obtained DNA samples from COVID-19 infected patients and evaluate for potential correlation between ACE2 variant frequencies in relationship to COVID-19 disease progression and mortalities between and within AAs and non-Hispanic Caucasian CAs subgroup;. COVID-19 is caused by SARS-CoV-2 which uses host cell ACE2, TMPRSS2, EZRIN and other proteins for entry. Differences in ACE2 or TMPRSS2/EZRIN genes expression and SNPs may justify the disease disparity and aim 2 will address how COVID-19 spike engagement with host cell receptor is precisely regulated and how host cells respond to cytokines elicited by COVID-19 infection using lung organoids. A recent correlation study suggested that the decrease expression of ACE2 /TMPRSS2/EZRIN are predictors of decreased susceptibility to COVID-19 infection and could be attributed to COVID-19 morbidity in Africa American patients. Aim-2: Modeling COVID-19-elicited disease disparity using lung organoids. Clinical validation of ACE2 and EZRIN will help to develop better strategies for COVID 19 diagnosis and treatment to reduce the observed COVID-19 disease progressive outcome and mortality gaps between African American and Caucasians patients. .", "keywords": [ "2019-nCoV", "ACE2", "Address", "Affect", "Africa", "African American", "American", "Bacteria", "Biology", "Blood specimen", "CCL2 gene", "COVID-19", "COVID-19 diagnosis", "COVID-19 morbidity", "COVID-19 mortality", "COVID-19 patient", "COVID-19 severity", "COVID-19 treatment", "Caucasians", "Cells", "Center for Translational Science Activities", "Clinical", "Correlation Studies", "DNA", "Data", "Diabetes Mellitus", "Disease", "Disease Progression", "Female", "Frequencies", "Gene Expression", "Genes", "Genetic", "Genetic Predisposition to Disease", "Genetic Variation", "Genomics", "Goals", "HLA Antigens", "Health", "Heart Diseases", "Hospitals", "Hypertension", "Image", "Immune response", "Incidence", "Individual", "Institutes", "Integration Host Factors", "Knowledge", "Lung", "Lung diseases", "Minority", "Modeling", "Molecular", "Morbidity - disease rate", "Morehouse School of Medicine", "Not Hispanic or Latino", "Obesity", "Organoids", "Outcome", "Patients", "Peripheral Blood Mononuclear Cell", "Play", "Population", "Positioning Attribute", "Predisposition", "Progressive Disease", "Proteins", "Receptor Cell", "Research", "Risk", "Role", "SARS-CoV-2 infection", "Sampling", "Series", "Socioeconomic Factors", "Statistical Study", "Subgroup", "TMPRSS2 gene", "Testing", "Validation", "Variant", "Virus", "Work", "X Chromosome", "chemokine", "comorbidity", "cytokine", "differential expression", "disease disparity", "ezrin", "genetic variant", "health disparity", "health inequalities", "high risk", "machine learning algorithm", "male", "mortality", "novel", "outcome prediction", "predictive modeling", "racial disparity", "receptor", "transcriptome sequencing", "underserved minority" ], "approved": true } }, { "type": "Grant", "id": "5543", "attributes": { "award_id": "3U54MD007602-34S3", "title": "Center for Translational Research in Health Disparities- RCMI Supplement Young Adult (18-24) Community Mental Health WorkersVaccine Hesitancy, Uptake and Community Engagement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 19248, "first_name": "Priscah", "last_name": "Mujuru", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-07-07", "end_date": "2023-05-31", "award_amount": 353127, "principal_investigator": { "id": 19249, "first_name": "Vincent C", "last_name": "Bond", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 755, "ror": "https://ror.org/01pbhra64", "name": "Morehouse School of Medicine", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Morehouse School of Medicine (MSM) vision as detailed in our current Strategic Plan is “leading the creation and advancement of health equity”. To accomplish this vision, and ultimately health equity, new structures are required. More rapid translation of research discoveries has been facilitated through a “team-based approach” to address the health of the people and communities. This means bringing biomedical, clinical, and behavioral investigators and others together in Multidisciplinary Translational Teams (MDTT’s) focused on a health disparity that bring to bear their combined expertise to address populations health translating discoveries into practical solutions. MSM RCMI Program has been successful at developing research infrastructure including researchers. This application has been developed to bring the expertise of the RCMI Program Cores, with Community and Clinical researchers and partners to build Multidisciplinary Translational Teams across the T spectrum targeted at more rapid translation of health disparities (e.g., Cancer, Stroke, Infectious Diseases, Cardiometabolic Disease, Reproductive Health) by expanding the baseline research infrastructure established by Morehouse School of Medicine. The primary objectives are to build those teams through research projects targeted at health disparities, and to develop a pipeline of developing research teams at MSM, and to increase the level of involvement of investigators in conducting MDTT research at MSM. The U54 Center for Translational Research in Health Disparities (CTRHD) consists of five Cores (Administrative, Research Infrastructure, Investigation Development, Community Engagement, and Recruitment); Three Research Projects; an evaluation component attached to the Administrative Core, and a Pilot Project Program attached to the Investigator Development Core. With these assets and activities, the CTRHD will accomplish its goal through the following Aims: AIM 1: Transform Our Institution. Build processes and structures facilitating development of competitive multidisciplinary translational teams (MDTTs), allowing MSM to emerge as the preeminent, research-intensive, minority serving academic health center in the nation. AIM 2: Transform the MSM Research Environment. Develop collaborations allowing MSM faculty to do cutting edge translational health disparities research. AIM 3: Transform the Community of Scientists. Promote and accelerate training and mentoring capabilities at MSM, leading to the next generation of leaders in health disparities multidisciplinary translational research. AIM 4. Transform Our Community. Facilitate integration of Basic Research with Community Engagement. Supplement In an effort to examine and decrease COVID-19 vaccination hesitancy among the Haitian American immigrant population, and to decrease mental health disparities among underserved youth, our team proposes to culturally adapt, implement, and conduct a preliminary validation of a youth (18-24) led health and mental health education campaign to address COVID-19 related psychosocial stressors. Our central hypothesis is that through participation in this program, young adults become active agents in the development of positive health outcomes for themselves, their families, and community. Participation in HSYACHW will encourage healthy behaviors and better health outcomes, while helping to mitigate the adverse emotional effects of COVID-19 and vaccine hesitancy among underserved young adults. Our objective is to utilize social ecological public health theory and Community-based Participatory approach to examine the sociodemographic factors involved in motivating young adults to develop strategies for influencing health outcomes at the individual, family, and community levels. This work also aims to foster the development and sustainability of positive health behaviors among medically underserved youth, their families and communities. This is a RCMI Supplemental project is to adapt and evaluate this approach. The specific aims are: 1) To adapt the High School & Young Adult Community Health Worker Training program for use with young adult refugee and Immigrant populations (ages 18-24) of Haitian descent; 2) To implement and validate the success of the adapted HSYACHW within the target population to vaccine hesitancy and uptake and improved mental health.", "keywords": [ "Academy", "Address", "Adolescent", "Adult", "Age", "American", "Awareness", "Basic Science", "Behavior", "Behavioral", "COVID-19", "COVID-19 vaccination", "COVID-19 vaccine", "Cardiometabolic Disease", "Center for Translational Science Activities", "Child", "Childhood", "Clinical", "Collaborations", "Communicable Diseases", "Communication", "Communities", "Community Health", "Community Health Aides", "Contact Tracing", "Contracts", "Critical Thinking", "Development", "Educational Curriculum", "Emotional", "Environment", "Evaluation", "Exercise", "Faculty", "Family", "Focus Groups", "Fostering", "Funding", "Goals", "Haitian", "Health", "Health Promotion", "Health Status", "Health behavior", "Healthy Eating", "Immigrant", "Individual", "Institution", "Instruction", "Intervention", "Investigation", "Journals", "Knowledge", "Link", "Malignant Neoplasms", "Measures", "Medicine", "Mental Health", "Mentors", "Minority", "Morbidity - disease rate", "Morehouse School of Medicine", "New York", "Nurses", "Nutritional", "Outcome", "Participant", "Pathway interactions", "Pilot Projects", "Policies", "Population", "Principal Investigator", "Process", "Psychologist", "Public Health", "Public Health Education", "Recording of previous events", "Refugees", "Reproductive Health", "Research", "Research Infrastructure", "Research Personnel", "Research Project Grants", "Research Proposals", "Resources", "Risk", "Schools", "Scientist", "Source", "Strategic Planning", "Stroke", "Structure", "Students", "Target Populations", "Training", "Training Programs", "Translating", "Translational Research", "Translations", "Trust", "Urban Health", "Ursidae Family", "Vaccination", "Validation", "Virus", "Vision", "Work", "Youth", "adolescent health", "base", "combat", "community engagement", "design", "disorder prevention", "empowerment", "experience", "health disparity", "health disparity populations", "health equity", "health literacy", "high school", "improved", "innovation", "intervention effect", "medically underserved", "medically underserved population", "member", "men", "mental health education", "mortality", "multidisciplinary", "news", "next generation", "online course", "population health", "preventive intervention", "programs", "psychologic", "psychosocial", "psychosocial stressors", "public health intervention", "recruit", "research and development", "satisfaction", "social", "social norm", "sociodemographic factors" ], "approved": true } }, { "type": "Grant", "id": "6709", "attributes": { "award_id": "5U54MD007602-35", "title": "Community Engagement Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22451, "first_name": "Priscah", "last_name": "Mujuru", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-07-07", "end_date": "2023-05-31", "award_amount": 329038, "principal_investigator": { "id": 22452, "first_name": "RONALD Lloyd", "last_name": "BRAITHWAITE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 755, "ror": "https://ror.org/01pbhra64", "name": "Morehouse School of Medicine", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 755, "ror": "https://ror.org/01pbhra64", "name": "Morehouse School of Medicine", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Morehouse School of Medicine (MSM) vision as detailed in our current Strategic Plan is “leading the creation and advancement of health equity”. To accomplish this vision, and ultimately health equity, new structures are required. More rapid translation of research discoveries has been facilitated through a “team-based approach” to address the health of the people and communities. This means bringing biomedical, clinical, and behavioral investigators and others together in Multidisciplinary Translational Teams (MDTT’s) focused on a health disparity that bring to bear their combined expertise to address populations health translating discoveries into practical solutions. MSM RCMI Program has been successful at developing research infrastructure including researchers. This application has been developed to bring the expertise of the RCMI Program Cores, with Community and Clinical researchers and partners to build Multidisciplinary Translational Teams across the T spectrum targeted at more rapid translation of health disparities (e.g., Cancer, Stroke, Infectious Diseases, Cardiometabolic Disease, Reproductive Health) by expanding the baseline research infrastructure established by Morehouse School of Medicine. The primary objectives are to build those teams through research projects targeted at health disparities, and to develop a pipeline of developing research teams at MSM, and to increase the level of involvement of investigators in conducting MDTT research at MSM. The U54 Center for Translational Research in Health Disparities (CTRHD) consists of five Cores (Administrative, Research Infrastructure, Investigation Development, Community Engagement, and Recruitment); Three Research Projects; an evaluation component attached to the Administrative Core, and a Pilot Project Program attached to the Investigator Development Core. With these assets and activities, the CTRHD will accomplish its goal through the following Aims: AIM 1: Transform Our Institution. Build processes and structures facilitating development of competitive multidisciplinary translational teams (MDTTs), allowing MSM to emerge as the preeminent, research-intensive, minority serving academic health center in the nation. AIM 2: Transform the MSM Research Environment. Develop collaborations allowing MSM faculty to do cutting edge translational health disparities research. AIM 3: Transform the Community of Scientists. Promote and accelerate training and mentoring capabilities at MSM, leading to the next generation of leaders in health disparities multidisciplinary translational research. AIM 4. Transform Our Community. Facilitate integration of Basic Research with Community Engagement. Supplement In an effort to examine and decrease COVID-19 vaccination hesitancy among the Haitian American immigrant population, and to decrease mental health disparities among underserved youth, our team proposes to culturally adapt, implement, and conduct a preliminary validation of a youth (18-24) led health and mental health education campaign to address COVID-19 related psychosocial stressors. Our central hypothesis is that through participation in this program, young adults become active agents in the development of positive health outcomes for themselves, their families, and community. Participation in HSYACHW will encourage healthy behaviors and better health outcomes, while helping to mitigate the adverse emotional effects of COVID-19 and vaccine hesitancy among underserved young adults. Our objective is to utilize social ecological public health theory and Community-based Participatory approach to examine the sociodemographic factors involved in motivating young adults to develop strategies for influencing health outcomes at the individual, family, and community levels. This work also aims to foster the development and sustainability of positive health behaviors among medically underserved youth, their families and communities. This is a RCMI Supplemental project is to adapt and evaluate this approach. The specific aims are: 1) To adapt the High School & Young Adult Community Health Worker Training program for use with young adult refugee and Immigrant populations (ages 18-24) of Haitian descent; 2) To implement and validate the success of the adapted HSYACHW within the target population to vaccine hesitancy and uptake and improved mental health.", "keywords": [ "Academy", "Address", "Adolescent", "Adult", "Age", "American", "Awareness", "Basic Science", "Behavior", "Behavioral", "COVID-19", "COVID-19 vaccination", "COVID-19 vaccine", "Cardiometabolic Disease", "Center for Translational Science Activities", "Child", "Childhood", "Clinical", "Collaborations", "Communicable Diseases", "Communication", "Communities", "Community Health", "Community Health Aides", "Contact Tracing", "Contracts", "Critical Thinking", "Development", "Educational Curriculum", "Emotional", "Environment", "Evaluation", "Exercise", "Faculty", "Family", "Focus Groups", "Fostering", "Funding", "Goals", "Haitian", "Health", "Health Disparities Research", "Health Promotion", "Health Status", "Health behavior", "Healthy Eating", "Immigrant", "Individual", "Institution", "Instruction", "Intervention", "Investigation", "Journals", "Knowledge", "Link", "Malignant Neoplasms", "Measures", "Medicine", "Mental Health", "Mentors", "Minority", "Morbidity - disease rate", "Morehouse School of Medicine", "New York", "Nurses", "Nutritional", "Outcome", "Participant", "Pathway interactions", "Persons", "Pilot Projects", "Policies", "Population", "Principal Investigator", "Process", "Psychologist", "Public Health", "Public Health Education", "Recording of previous events", "Refugees", "Reproductive Health", "Research", "Research Infrastructure", "Research Personnel", "Research Project Grants", "Research Proposals", "Resources", "Risk", "Schools", "Scientist", "Source", "Strategic Planning", "Stroke", "Structure", "Students", "Target Populations", "Training", "Training Programs", "Translating", "Translational Research", "Translations", "Trust", "Urban Health", "Ursidae Family", "Vaccination", "Validation", "Virus", "Vision", "Work", "Youth", "adolescent health", "base", "combat", "community engagement", "design", "disorder prevention", "empowerment", "experience", "health disparity", "health disparity populations", "health equity", "health literacy", "high school", "improved", "innovation", "intervention effect", "long term consequences of COVID-19", "medically underserved", "medically underserved population", "member", "men", "mental health education", "mortality", "multidisciplinary", "news", "next generation", "online course", "population health", "preventive intervention", "process evaluation", "programs", "psychologic", "psychosocial", "psychosocial stressors", "public health intervention" ], "approved": true } }, { "type": "Grant", "id": "6982", "attributes": { "award_id": "3U54MD007585-30S1", "title": "Promoting the Desire to participate in Covid-19 Vaccination among Underserved Rural and Minority Communities in Alabama: The WeCARE proposal.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 8046, "first_name": "Nathaniel", "last_name": "Stinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-07-07", "end_date": "2023-08-31", "award_amount": 242550, "principal_investigator": { "id": 21075, "first_name": "Clayton", "last_name": "Yates", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 569, "ror": "https://ror.org/0137n4m74", "name": "Tuskegee University", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 569, "ror": "https://ror.org/0137n4m74", "name": "Tuskegee University", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "The overall objective of the Tuskegee University Center for Biomedical Research/Research Centers in Minority Institutions (TU CBR/RCMI) Program is to build upon and develop the University’s research infrastructure and researchers to conduct research related to health disparities. This initiative is centered around: 1) providing the necessary infrastructure, resources, services, and technical support to enhance the ability of the University’s researchers to stay on the cutting-edge of multidisciplinary biomedical research focused on health disparities and 2) supporting the research and career development of junior- and mid-level investigators. These objectives are to be achieved primarily through the following aims: 1) Provide pilot-level funding to support the development and expansion of the biomedical research capacity of TU; 2) Provide core research facilities equipped with the infrastructure, instrumentation, and personnel to support the needs of the TU research community; 3) Engage the community through RCMI-sponsored activities that include the research faculty; and 4) Provide mentorship and career guidance to enhance the transition of junior-level investigators into independent scientists. The overall goal of the CBR/RCMI project (2017-2022) is to continue the development of its infrastructure and increase the numbers and skill proficiency of minority scientists engaged in advanced biomedical research focused on health disparities, including those for HIV, obesity, and prostate cancer, all of which disproportionately affect African Americans and underrepresented minorities. In other words, the goal is to continue support for a competitive, multidisciplinary collaborative environment that advances biomedical research. Tuskegee University has distinctive strengths because it is located in the heart of the Southeast, a region with a large, historically underserved, African American population, and it has a large number of minority faculty members as well as undergraduate and graduate trainees. The goal of the CBR/RCMI will be accomplished through establishment of three synergistic research cores, with services to enable investigative research on health inequities among minority groups, especially African-Americans residing in the ‘Black Belt’ counties of Alabama. These cores create a stimulating environment that promotes a culture of efficient and timely administrative support that will increase the number of funding submissions and/or acquisitions of extramural funding in biomedical and community engagement research. The Administrative Core will provide multi-functional support through pre- and post-award services; implementation of objectives, directions, and guidance; and oversight to ensure that specific aims and objectives are accomplished. Additionally, the Investigator Development Core will support the development of additional areas of research while enhancing the growth of junior faculty through senior mentorship and bioethics training. Further, through our community engagement core, we will establish relationships, build trust, and engage local communities and community-based organizations to learn from and to educate community members on health issues that affect them. We will also implement an evaluation plan to assess, over a period of five years, the progress, productivity, and accountability of the CBR by using both formative and summative outcomes. The outcome is to increase, by an approved and enforceable protocol that focuses on junior faculty development and productivity, the number of R-type grants awarded and the number of publications in peer- reviewed journals. The availability of advanced research equipment, coupled with the new knowledge generated by TU PhD students, scientists, and collaborators will contribute to the reduction of health disparities in the Black Belt counties of Alabama.", "keywords": [ "Accountability", "Address", "Affect", "African American", "Alabama", "Applications Grants", "Area", "Award", "Behavioral Research", "Bioethics", "Bioinformatics", "Biomedical Research", "Biometry", "COVID-19 vaccination", "Collaborations", "Communities", "Community Outreach", "Computational Biology", "Core Facility", "County", "Coupled", "Deep South", "Development", "Doctor of Philosophy", "Education", "Educational process of instructing", "Educational workshop", "Ensure", "Environment", "Equipment", "Evaluation", "Exercise", "Extramural Activities", "Faculty", "Fostering", "Foundations", "Funding", "Goals", "Government", "Grant", "Growth", "HIV", "Health", "Heart", "Human Resources", "Infrastructure", "Institution", "Journals", "Knowledge", "Learning", "Location", "Malignant Neoplasms", "Malignant neoplasm of prostate", "Maps", "Mentors", "Mentorship", "Minority", "Minority Groups", "Minority-Serving Institution", "Mission", "Molecular", "Obesity", "Outcome", "Peer Review", "Population", "Positioning Attribute", "Productivity", "Protocols documentation", "Publications", "Research", "Research Infrastructure", "Research Personnel", "Research Project Grants", "Research Support", "Resources", "Rural Community", "STEM career", "Science", "Science Technology Engineering and Mathematics Education", "Scientist", "Services", "Solid", "Teacher Professional Development", "Time", "Training", "Trust", "Underrepresented Minority", "Underrepresented Populations", "Underserved Population", "Universities", "Vocational Guidance", "Work", "base", "biological research", "career", "career development", "collaborative environment", "community based research", "community engagement", "design", "doctoral student", "ethnic minority population", "experience", "faculty research", "health disparity", "health inequalities", "instrumentation", "inter-institutional", "interest", "learning community", "member", "minority communities", "minority health", "minority scientist", "minority student", "multidisciplinary", "outreach services", "programs", "racial health disparity", "research and development", "research facility", "rural underserved", "skills", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "7094", "attributes": { "award_id": "3P30CA016056-43S3", "title": "Phase IbTrial of Rintatolimod and IFNa Regimen in Cancer Patients with Mild or Moderate COVID-19 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22891, "first_name": "Min", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-06-16", "end_date": "2024-04-30", "award_amount": 420500, "principal_investigator": { "id": 22892, "first_name": "CANDACE S.", "last_name": "JOHNSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1148, "ror": "", "name": "ROSWELL PARK CANCER INSTITUTE CORP", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1148, "ror": "", "name": "ROSWELL PARK CANCER INSTITUTE CORP", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Following infection with the novel coronavirus SARS-CoV-, immunocompromised and older individuals are at higher risk of severe illness and fatality. Patients with cancer exhibit multiple factors associated with elevated morbidity and mortality from COVID-19, including older age, pre-existing cardiac and lung disease, and immune impairment from the underlying malignancy and chemotherapy. While the innate immune response is the first line of antiviral defense against SARS-CoV-2, coronavirus infection is accompanied by suppression of type I interferon (IFN), thereby limiting activation of innate immune pathways required for immediate control of infection and adaptive immunity. Coronavirus-mediated inhibition of innate immunity via the type I IFN pathway allows the virus to replicate in epithelial cells, and particularly in high-risk patients, progress to pneumonia and respiratory failure. The mechanisms include inhibition of intracellular signaling driven by pattern recognition receptors (e.g. RIG-I and MDA5) and suppression of IRF-3, a transcriptional factor that induces the expression of type 1 interferons. Consequently, we hypothesize that augmentation of innate immunity during early mild or moderately severe infection might avert progression to respiratory failure and mortality. Rintatolimod, a selective dsRNA ligand of TLR3, has strong antiviral activity against multiple viruses including the coronavirus SARS-CoV-1 in vitro and in animal models. The combination of recombinant IFN (Intron-A) and rintatolimod is currently being evaluated in clinical trials developed by our group at Roswell Park (NCT03403634, NCT03599453, NCT03899987) for patients with multiple solid tumors. In this proposal, we will re-purpose these agents to test whether the synergistic combination therapy will overcome the defective ability to induce type I IFN and stimulate TLR-mediated immune activation to provide protection from viral infection. Patients with cancer and mild or moderate COVID-19 within the Roswell Park catchment area will be enrolled over 6 months. Roswell Park has been selected by New York State as a regional testing area for COVID-19. The principal endpoint is safety of rintatolimod and Intron-A. Secondary endpoints are: (i) progression of infection requiring hospitalization; (ii) respiratory failure requiring mechanical ventilation; and (iii) death within 30 days Biospecimens collected from all patients will be used for translational assays, including kinetics of 1) viral clearance from nasal swabs and serum; 2) circulating inflammatory mediators; and 3) immunophenotype of lymphocyte subsets. Overall significance: We will repurpose the combination of two antiviral agents, which showed safety and promising results in patients with advanced cancer, to stop viral replication and mitigate the risk of progression to severe COVID19 in patients with cancer and SARS-CoV-2 infection. We expect to establish the safety of rIFNα and Rintatolimod in patients with cancer and COVID-19 and create the foundation for a larger multi-center randomized trial to test efficacy.", "keywords": [ "2019-nCoV", "Advanced Malignant Neoplasm", "Age", "Animal Model", "Antiviral Agents", "Area", "Award", "Basic Science", "Biological Assay", "COVID-19", "Cancer Center", "Cancer Center Support Grant", "Cancer Patient", "Cancer Science", "Catchment Area", "Cessation of life", "Clinic", "Clinical", "Clinical Trials", "Combined Modality Therapy", "Communities", "Community Outreach", "Comprehensive Cancer Center", "Coronavirus", "Coronavirus Infections", "Country", "Development", "Discipline", "Double-Stranded RNA", "Enrollment", "Epithelial Cells", "Exhibits", "Faculty", "Faculty Recruitment", "Foundations", "Funding", "Genomic medicine", "Grant", "Growth", "Heart Diseases", "Hospitalization", "Human Resources", "Immune", "Immunocompromised Host", "Impairment", "In Vitro", "Individual", "Infection", "Infection Control", "Inflammation Mediators", "Infrastructure", "Innate Immune Response", "Interferon Type I", "Interferon-alpha", "Interferons", "Intervention", "Introns", "Kinetics", "Laboratories", "Leadership", "Ligands", "Lung diseases", "Lymphocyte Immunophenotypings", "Lymphocyte Subset", "Malignant Neoplasms", "Mechanical ventilation", "Mediating", "Mission", "Molecular Epidemiology", "Morbidity - disease rate", "National Cancer Institute", "Natural Immunity", "New York", "Nose", "Oncology", "Pathway interactions", "Patients", "Pattern recognition receptor", "Phase", "Play", "Pneumonia", "Population", "Population Sciences", "Prevention education", "Prevention strategy", "Recombinants", "Recording of previous events", "Regimen", "Request for Applications", "Research", "Research Personnel", "Resource Sharing", "Resources", "Respiratory Failure", "Risk", "Role", "SARS coronavirus", "Safety", "Science", "Scientist", "Serum", "Signal Transduction", "Solid Neoplasm", "Swab", "TLR3 gene", "Testing", "Therapeutic", "Training", "Viral", "Virus", "Virus Diseases", "Virus Replication", "adaptive immunity", "anticancer research", "cancer care", "cancer education", "cancer prevention", "cancer therapy", "chemotherapy", "efficacy testing", "experience", "high risk", "immune activation", "innate immune pathways", "innovation", "investigator-initiated trial", "member", "mortality", "neoplasm immunotherapy", "next generation", "novel coronavirus", "outreach", "peer", "population based", "prevent", "programs", "randomized trial", "recruit", "secondary endpoint", "survivorship", "transcription f" ], "approved": true } }, { "type": "Grant", "id": "6123", "attributes": { "award_id": "3P51OD010425-60S1", "title": "Impact of pre-existing SARS-CoV-2 immunity on vaccination against new variants", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 20815, "first_name": "MATTHEW ERIN", "last_name": "Arnegard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-06-10", "end_date": "2022-04-30", "award_amount": 499999, "principal_investigator": { "id": 20816, "first_name": "SEAN D", "last_name": "SULLIVAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The deployment of efficacious SARS-CoV-2 vaccines has prevented the death of millions of people. New SARS- CoV-2 variants that are more transmissible exhibit increased resistance to neutralizing antibodies elicited by either the current vaccine or by prior infection with the original strain. To address this, we have developed a 2nd generation COVID19 vaccine that employs a self-amplifying replicon RNA (repRNA) and is delivered using a novel nanolipid carrier formulation (LION) that can be rapidly scaled up and is more stable at warmer temperatures to support effective worldwide distribution. Our repRNA vaccine expresses a structurally intact receptor binding domain (RBD) immunogen (called SHARP) that matches variants exhibiting resistance to neutralization by current vaccines. Second generation vaccines like this one will be administered to people that are already pre-immune to earlier variants of SARS-CoV-2 due to prior immunization or infection but, to date, the impact of pre-immunity to the original variants on these new vaccines is not known. Pre-immunity may enable the new vaccines to induce even broader antibody responses against different variants. On the other hand, original antigenic sin (OAS), wherein the immune response to an infection preferentially recalls memory cells primed by the first antigenic exposure, could dampen efficacy of 2nd generation vaccines if upon exposure to the new variant, B cell responses primed by the original variant are preferentially recalled. To gain a better understanding of the impact of pre-existing immunity on 2nd generation COVID-19 vaccines, we propose a pilot study using a repRNA vaccine expressing SHARP to immunize macaques with pre-existing immunity to the original D614G variant due to prior immunization. Our goal is to determine if pre-immunity improves or, alternatively, dampens the immunogenicity and/or protective efficacy of 2nd generation vaccines designed to protect against new variants. These questions are best addressed in NHPs that closely model the repertoire of innate and adaptive immune responses in humans and can be challenged with SARS-CoV-2 to investigate the impact on protective efficacy and recall responses. Our Aims are: 1) Characterize the magnitude, specificity and type of immune responses induced in macaques pre-immune to the original D614G variant and boosted with a a repRNA vaccine expressing the B.1351 variant immunogen. 2) Investigate pathogenesis of B.1351 infection in pigtail macaques, protective efficacy of the repRNA B.1351 SHARP vaccine in pre-immune macaques, and immune correlates of protection. 3) Determine the impact of prior immunization with the original D614G variant on innate immune responses and their role in the immunogenicity and efficacy of the 2nd generation repRNA B.1351 SHARP vaccine. Knowledge gained on the impact of pre-immunity from this study will have broader implications for the development of this and other 2nd generation vaccines. If successful, this study will also support further development and evaluation of a trivalent repRNA SHARP vaccine that is more amenable for worldwide distribution than current mRNA vaccines and could provide broad protection against multiple variants.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Alphavirus", "Angiotensin Receptor", "Antibody Repertoire", "Antibody Response", "Antigens", "B-Lymphocytes", "Binding", "COVID-19", "COVID-19 vaccine", "Cells", "Cessation of life", "Data", "Development", "Dose", "Evaluation", "Evolution", "Exhibits", "Exposure to", "Formulation", "Funding", "Generations", "Genome", "Goals", "Human", "Immune", "Immune response", "Immunity", "Immunization", "Immunize", "Individual", "Infection", "Influenza Hemagglutinin", "Innate Immune Response", "Knowledge", "Lipids", "Macaca", "Macaca nemestrina", "Measures", "Mediating", "Modeling", "Mutation", "Pathogenesis", "Pilot Projects", "Population", "Proteins", "RNA", "RNA vaccine", "Replicon", "Resistance", "Role", "SARS-CoV-2 immunity", "SARS-CoV-2 infection", "SARS-CoV-2 transmission", "SARS-CoV-2 variant", "Secondary Immunization", "Ships", "Specificity", "Structure", "Systems Biology", "T cell response", "Temperature", "Update", "Vaccinated", "Vaccination", "Vaccine Design", "Vaccines", "Variant", "Venezuelan Equine Encephalitis Virus", "Viral", "Virus", "adaptive immune response", "base", "design", "immunogenicity", "improved", "memory recall", "nanocarrier", "neutralizing antibody", "novel", "novel vaccines", "prevent", "protective efficacy", "receptor binding", "response", "scale up", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "6482", "attributes": { "award_id": "3P30CA046592-31S2", "title": "Targeting TMPRSS2 expression as a therapy for coronavirus infection and replication", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21751, "first_name": "Precilla L.", "last_name": "Belin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-06-01", "end_date": "2023-05-31", "award_amount": 390000, "principal_investigator": { "id": 21752, "first_name": "Eric R.", "last_name": "Fearon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronaviruses employ two key host proteins to gain entry and replicate within cells, angiotensinconverting enzyme 2 (ACE2), an essential receptor of entry, and cell surface transmembrane protease serine 2 (TMPRSS2), a serine protease that cleaves coronavirus spike proteins following receptor binding to promote viral fusion and entry into cells. Chemical inhibitors and RNA interference of TMPRSS2 have been shown to markedly slow coronavirus entry and replication in human lung epithelial cell lines. In vivo studies with TMPRSS2 transgenic knockout mice have further shown that loss of TMPRSS2 can reduce coronavirus replication in lungs, elicit a weaker proinflammatory response, and result in milder lung pathology. Importantly, initial data stemming from studies on the novel coronavirus responsible for the COVID-19 pandemic, SARS-CoV-2, show that viral entry mechanisms appear similar to other coronavirus family members, as SARS-CoV-2 entry into cells is decreased upon TMPRSS2 inhibition. Altogether, these data strongly suggest that modulation of TMPRSS2 levels may be an effective treatment strategy for patients infected with SARS-CoV-2. The Chinnaiyan lab discovered TMPRSS2 as the androgen-regulated 5’ partner of the TMPRSS2- ERG and TMPRSS2-ETS family of prostate cancer gene fusions. TMPRSS2 expression is directly regulated by the androgen receptor (AR), which has been extensively studied and targeted through various therapeutic interventions for the treatment of prostate cancer. Preliminary data from our lab suggests that lung TMPRSS2 is also androgen-regulated. Notably, several FDA-approved agents targeting AR activity in prostate cancer, such as enzalutamide, can markedly inhibit TMPRSS2 expression through antagonism of AR. We, therefore, hypothesize that FDA-approved drugs that markedly inhibit TMPRSS2 expression, like enzalutamide, may be effective in inhibiting coronavirus replication and possibly infection. Recent data from Italy (and other countries) suggests that males, who implicitly have higher levels of androgen than females, die of coronavirus by a factor of two-to-one, providing orthogonal evidence that AR activity may indeed be a player in COVID-19 progression. Thus, we would like to quickly generate pre-clinical data to support the idea that agents that suppress AR/TMPRSS2 may be repurposed to treat or prevent coronavirus infection. Based on this pre-clinical data, we would quickly assemble a clinical team to initiate a clinical trial investigating FDAapproved AR antagonists in patients infected with SARS-CoV-2. Critically, most samples for these studies are already banked in our lab to support an accelerated timeline, and since agents like enzalutamide are FDA-approved, this project could have immediate clinical impact for COVID-19 patients.", "keywords": [ "2019-nCoV", "Achievement", "Address", "Affect", "Androgen Antagonists", "Androgen Receptor", "Androgens", "Behavior", "Behavioral", "Behavioral Research", "COVID-19", "COVID-19 pandemic", "Cancer Burden", "Cancer Patient", "Cancer Survivor", "Caring", "Catchment Area", "Cell Line", "Cell surface", "Cells", "Chemicals", "Cleaved cell", "Clinical", "Clinical Data", "Clinical Investigator", "Clinical Trials", "Communities", "Complement", "Coronavirus", "Coronavirus Infections", "Coronavirus spike protein", "Country", "Data", "Decision Making", "Development", "Diagnosis", "Diet", "Early Diagnosis", "Education", "Education and Outreach", "Environment", "Enzymes", "Epigenetic Process", "Epithelial Cells", "Event", "FDA approved", "Faculty Recruitment", "Family", "Family member", "Female", "Foundations", "Funding", "Funding Mechanisms", "Future Generations", "Gene Expression", "Gene Fusion", "Genetic", "Genomics", "Germ-Line Mutation", "Goals", "Grant", "Hormonal", "Human", "Image", "Immune", "Improve Access", "Infection", "Italy", "Knockout Mice", "Knowledge", "Lesion", "Life Style", "Lung", "Malignant Neoplasms", "Malignant neoplasm of prostate", "Mission", "Molecular", "NCI Center for Cancer Research", "Neoplasms", "Nucleic Acids", "Outcome", "Pathogenesis", "Patient-Focused Outcomes", "Patients", "Pharmaceutical Preparations", "Pharmacology", "Phenotype", "Plant Roots", "Population", "Positioning Attribute", "Prevention", "Prevention approach", "Prostate Cancer therapy", "Proteins", "Provider", "Pulmonary Pathology", "Quality of Care", "RNA Interference", "Research", "Research Personnel", "Resource Sharing", "Risk", "Risk Assessment", "Risk Reduction", "Sampling Studies", "Science", "Serine Protease", "Signal Pathway", "Signal Transduction", "Somatic Mutation", "Structure", "TMPRSS2 gene", "Therapeutic Intervention", "TimeLine", "Training", "Transgenic Organisms", "Translating", "Treatment outcome", "University of Michigan Comprehensive Cancer Center", "Viral", "Vision", "base", "cancer care", "cancer health disparity", "cancer prevention", "cancer risk", "cancer therapy", "cancer type", "care delivery", "career", "clinically significant", "effective therapy", "imaging approach", "implementation research", "improved", "in vivo", "inhibitor/antagonist", "innovation", "interdisciplinary collaboration", "lifestyle factors", "male", "member", "microbial", "novel", "novel coronavirus", "novel strate" ], "approved": true } }, { "type": "Grant", "id": "7783", "attributes": { "award_id": "3P30CA013330-48S4", "title": "Novel Biologics to Treat Lung Cancer and COVID-19 Comorbidity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 20549, "first_name": "Sonya", "last_name": "Roberson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-06-01", "end_date": "2022-06-30", "award_amount": 167791, "principal_investigator": { "id": 23589, "first_name": "STEVEN C.", "last_name": "ALMO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 741, "ror": "https://ror.org/05cf8a891", "name": "Albert Einstein College of Medicine", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22544, "first_name": "EDWARD", "last_name": "CHU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 741, "ror": "https://ror.org/05cf8a891", "name": "Albert Einstein College of Medicine", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 741, "ror": "https://ror.org/05cf8a891", "name": "Albert Einstein College of Medicine", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Novel Biologics to Treat Lung Cancer and COVID-19 Comorbidity: Analyses of patients with COVID-19 treated at the Montefiore Medical Center (University Hospital of the Albert Einstein College of Medicine) indicate a high mortality (28%) in cancer patients, in general, and a 55% mortality in patients with lung cancer, especially those that received lung radiation 1-12 months prior to COVID-19 diagnosis. We propose to study the role that CD8 T cell depletion plays as a determinant of this adverse outcome, as CD8 T cells have been shown to provide substantial protection from lethal severe acute respiratory syndrome due to coronavirus infection. We are exploiting a novel biologics platform to provide mechanistic insight into the impact of radiation therapy on the number and quality of protective lung-resident COVID-19 T specific cells. This platform, termed synTac (artificial immunological Synapse for T-cell Activation), selectively modulates specific disease-relevant T cell clones for targeted treatment of malignancies, autoimmune disease and infectious diseases. In this unique design, single chain peptide-MHC (sc-pMHC) constructs are covalently linked to a variety of costimulatory, coinhibitory and cytokine molecules. The sc-pMHC domain acts as an “address” to target specific T cell clones for delivery of a range of comodulatory domains (MODS), resulting in clonal-selective T cell modulation, thus eliminating the side effects of current immunotherapeutics, which elicit global immune modulation (i.e., stimulation or inhibition of all T cells). This technology is the foundation of Cue Biopharma (Almo, founder), a publically traded immunotherapy company focused on development and application of this platform. A synTac containing the HPV-derived E7 peptide and IL-2 cytokine elicits selective T cell expansion and tumor growth inhibition of an E7-driven tumor in pre-clinical models. The human analog of this synTac (CUE-101) is in a Phase 1 clinical trial for head/neck squamous cell carcinoma - HNSCC (NCT03978689) demonstrating favorable tolerability and drug exposure. Preclinical studies demonstrated antitumor efficacy as monotherapy and with anti-PD1 treatment. Based upon these findings, Merck, collaborating with Cue Biopharma, is launching a Phase I first-line study of CUE-101 in combination with Keytruda for HPV+ advanced HNSCC. We have adapted this platform to generate viral-targeted synTacs, possessing antigenic peptides for HIV and CMV, to deliver costimulatory signals through CD28 or 4-1BB receptors. These reagents support substantial in vivo expansion of HIV- and CMV-specific T cells (in the NGS murine system), and this platform is being expanded to utilize COVID-19 derived peptides for selective in vivo expansion of protective CD8 T cells for COVID-19 treatment and cancer/radiation comorbidities.", "keywords": [ "2019-nCoV", "Address", "Affect", "African American", "Angiotensin Receptor", "Applications Grants", "Autoimmune Diseases", "Binding", "Biological", "CD147 antigen", "CD28 gene", "CD8-Positive T-Lymphocytes", "COVID-19", "Cancer Patient", "Case Fatality Rates", "Cells", "Cessation of life", "Clinical Data", "Clone Cells", "Cohort Studies", "Colorectal Cancer", "Communicable Diseases", "Coronavirus Infections", "County", "Cues", "Cytomegalovirus", "Data Set", "Death Rate", "Development", "Diagnosis", "Disease", "Drug Exposure", "Ethnic Origin", "Failure", "Foundations", "Functional disorder", "Future", "General Population", "HIV", "Head and Neck Squamous Cell Carcinoma", "Hispanics", "Human", "Human Papillomavirus", "Immunity", "Immunotherapeutic agent", "Immunotherapy", "Impairment", "Infection", "Infection Control", "Institution", "Interleukin-2", "Invaded", "Knowledge", "Lead", "Link", "Lung", "Malignant - descriptor", "Malignant Neoplasms", "Malignant neoplasm of gastrointestinal tract", "Malignant neoplasm of lung", "Mediating", "Medical center", "Medicine", "Minority", "Mus", "Natural History", "New York City", "Organ", "Patients", "Pattern", "Peptide/MHC Complex", "Peptides", "Peptidyl-Dipeptidase A", "Phase", "Phase I Clinical Trials", "Play", "Pneumonia", "Policies", "Population", "Pre-Clinical Model", "Protocols documentation", "Race", "Radiation", "Radiation therapy", "Reagent", "Risk", "Role", "Serine Protease", "Severe Acute Respiratory Syndrome", "Signal Transduction", "Site", "Statistical Models", "System", "T-Cell Activation", "T-Cell Depletion", "T-Lymphocyte", "TMPRSS2 gene", "Technology", "Treatment outcome", "United States", "University Hospitals", "Viral", "Viral Load result", "Viral Proteins", "Virus", "Virus Receptors", "Virus Shedding", "adverse outcome", "analog", "anti-PD1 therapy", "base", "cancer type", "college", "colon cancer patients", "comorbidity", "coronavirus disease", "cytokine", "data modeling", "design", "gastrointestinal", "high risk", "immunological synapse", "immunoregulation", "in vivo", "insight", "mortality", "novel", "pandemic disease", "preclinical study", "receptor", "seroconversion", "side effect", "targeted treatment", "tumor", "tumor growth" ], "approved": true } }, { "type": "Grant", "id": "5040", "attributes": { "award_id": "3P51OD011104-61S1", "title": "Reprogramming of glucose metabolism and urea cycle in Long-COVID", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 18042, "first_name": "MATTHEW ERIN", "last_name": "Arnegard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-05-09", "end_date": "2023-04-30", "award_amount": 347577, "principal_investigator": { "id": 18043, "first_name": "L Lee", "last_name": "HAMM", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 18044, "first_name": "JAY", "last_name": "RAPPAPORT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "This application is a supplement request to our P51 base grant to Tulane National Primate Research Center (TNPRC) to further the investigation of Post-Acute Sequelae of SARS-CoV-2 infection (PASC). This application proposes to investigate the overarching hypothesis that virus-induced gut dysfunction, microbial translocation and downstream interferon signaling induce dysregulation of metabolic pathways involved in glucose metabolism and the urea cycle in the liver, the latter functioning to remove toxic ammonia from the body. We hypothesize that these alterations contribute to major pathogenic features of CoVID-19 infection and PASC, particularly chronic fatigue, neurocognitive disturbances, and dysregulation of glucose utilization contributing to type 2 diabetes, which has increased prevalence in persons previously infected with SARS- CoV-2. Alterations in the urea cycle may also promote clotting disorders associated with severe SARS-CoV-2 infection. Predisposition to thrombus formation has been observed in persons with ornithine transcarbamylase deficiency, an enzyme within the urea cycle pathway converting ornithine to citrulline. Indeed, in our preliminary data, we present supportive evidence of reduced citrulline levels in severe CoVID-19 patients. This application leverages our ongoing studies PASC in the African green monkey providing all the necessary samples for this investigation. This application also takes advantage of the CoVID-19 NHP Coordinating Center at TNPRC where we and three other Centers are engaged in Long-CoVID studies and will deposit our data for further analysis. Addition therapeutic studies will be performed in hACE2 transgenic mice, K18, which our team has published on previously as a model for SARS-CoV-2 infection, utilizing nutritional supplements and compounds to restore metabolic function during infection. This application represents a novel inquiry into an exciting hypothesis that may provide new insights into novel and effective therapeutic strategies for SARS- CoV-2 infection and PASC.", "keywords": [ "2019-nCoV", "Adverse effects", "African Green Monkey", "Ammonia", "Animals", "Antioxidants", "Antiviral Response", "Autoimmune", "Autopsy", "Award", "Biogenesis", "Biological", "Blood Coagulation Disorders", "COVID-19", "COVID-19 patient", "Cells", "Cellular Metabolic Process", "Chronic", "Citric Acid Cycle", "Citrulline", "Data", "Deposition", "Diabetes Mellitus", "Disease", "Drug Combinations", "Drug Metabolic Detoxication", "Enzymes", "Equilibrium", "Evaluation", "Evolution", "Fatigue", "Female", "Functional disorder", "Genes", "Glucose", "Glucose-6-Phosphate", "Goals", "Grant", "HIV", "Health", "Homeostasis", "Human", "Immune", "Immunologics", "Infection", "Inflammasome", "Inflammatory", "Interferons", "Investigation", "K-18 conjugate", "Kinetics", "Lactic acid", "Liver", "Long COVID", "Lung", "Macaca mulatta", "Mediating", "Metabolic", "Metabolic Diseases", "Metabolic Pathway", "Metabolic dysfunction", "Metabolism", "Mitochondria", "Modeling", "Mus", "Neurocognitive", "Non-Insulin-Dependent Diabetes Mellitus", "Nutrient", "Ornithine", "Ornithine carbamoyltransferase deficiency", "Pancreas", "Papio", "Parents", "Pathogenicity", "Pathway interactions", "Peripheral Blood Mononuclear Cell", "Permeability", "Persons", "Plasma", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predisposition", "Prevalence", "Primates", "Publishing", "Pulmonary Pathology", "Reporting", "Research", "SARS coronavirus", "SARS-CoV-2 infection", "Sampling", "Signal Transduction", "Specimen", "Succinic Acids", "Syndrome", "System", "Testing", "Therapeutic", "Therapeutic Studies", "Thrombus", "Tight Junctions", "Time", "Tissues", "Transgenic Mice", "Urea cycle disorders", "Vaccines", "Virus", "Whole Blood", "alpha ketoglutarate", "animal model development", "base", "blood glucose regulation", "brain fog", "design", "dietary supplements", "gastrointestinal symptom", "glucose metabolism", "gut dysbiosis", "improved", "insight", "male", "metabolic profile", "metabolome", "microbial", "mouse model", "nervous system disorder", "nonhuman primate", "novel", "novel therapeutic intervention", "response", "severe COVID-19", "success", "therapeutically effective", "urea cycle", "virology" ], "approved": true } }, { "type": "Grant", "id": "5076", "attributes": { "award_id": "3P51OD011132-62S2", "title": "Emory National Primate Research Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 18133, "first_name": "MATTHEW ERIN", "last_name": "Arnegard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-05-01", "end_date": "2026-04-30", "award_amount": 499995, "principal_investigator": { "id": 18134, "first_name": "JONATHAN S", "last_name": "LEWIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "OVERALL – SUMMARY/ABSTRACT This application seeks five years of continued support for the P51 Base Grant (OD 011132) for the operation of the Yerkes National Primate Research Center of Emory University. The overarching goals of the Yerkes Center are to conduct research programs focused on scientific problems relevant to human health and the NIH mission by providing resource infrastructure and expertise in appropriate scientific and veterinary specialties and to ensure the Center’s ability to serve as a resource to Core and Affiliated Scientists, as well as to other scientists regionally, nationally and internationally. During the current reporting period (5/1/2016 to present), the Yerkes Center has recorded remarkable progress, as evidenced by numerous (>550) publications, construction of new animal facilities, and continued robust research funding. In addition, the Yerkes Primate Center has maintained outstanding core research programs and provided resources and services to a broad multidisciplinary network of affiliate and collaborative investigators throughout the region and nation. These research programs, which involve the use of a variety of nonhuman primate species, are directed primarily toward four major research disciplines, representing the research divisions within the Yerkes Center: 1) Microbiology and Immunology; 2) Developmental and Cognitive Neuroscience, 3) Neuropharmacology and Neurologic Diseases and 4) Behavioral Neuroscience and Psychiatric Disorders. Also, through the Divisions of Animal Resources and Pathology, Yerkes provides support for outside investigators conducting research at the Yerkes Center, consistent with our ORIP-mandated role as a regional and national resource. Specific aims for the upcoming period of support include: 1) To carry out basic and translational research using nonhuman primates to expand knowledge, develop improved treatments, and advance cures that will benefit humanity; 2) To provide regional and national resources for data, consultative expertise, biologic materials, and specialized facilities useful in supporting nonhuman primate research; 3) To study basic nonhuman primate biology and improve nonhuman primate breeding, husbandry, and genetic characterization to better serve the biomedical research community; and 4) To provide research and training opportunities involving nonhuman primates to graduate and undergraduate students, postdoctoral fellows, visiting scientists, and faculty members. The pursuit of these aims will enhance the Center’s ability to serve as an enabling resource to Core and Affiliate Scientists for the conduct of nonhuman primate research, all for the ultimate goal of advancing the health and well-being of human and nonhuman primates.", "keywords": [ "Animal Housing", "Basic Science", "Behavioral", "Behavioral Research", "Biocompatible Materials", "Biology", "Biomedical Research", "Breeding", "Communities", "Consultations", "Development", "Discipline", "Ensure", "Faculty", "Funding", "Genetic", "Goals", "Grant", "Guidelines", "Health", "Housing", "Human", "Immunology", "Infrastructure", "International", "Knowledge", "Laboratory Research", "Mental disorders", "Microbiology", "Mission", "Neuropharmacology", "Neurosciences", "Pathology", "Personal Satisfaction", "Postdoctoral Fellow", "Primates", "Process", "Publications", "Reporting", "Research", "Research Infrastructure", "Research Personnel", "Research Training", "Resources", "Role", "Scientist", "Services", "Social Behavior", "Strategic Planning", "Translational Research", "United States National Institutes of Health", "Universities", "Visit", "animal facility", "animal resource", "base", "cognitive neuroscience", "data resource", "graduate student", "improved", "innovation", "laboratory facility", "medical specialties", "member", "multidisciplinary", "nervous system disorder", "nonhuman primate", "operation", "programs", "training opportunity", "undergraduate student" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1405, "count": 14046 } } }